Verona Pharma - שווי שוק בספרים VRNA

Steady demand for its patented lung therapy provides Verona Pharma plc (VRNA) with business resilience. However, international disputes and trade restrictions create risks for raw material logistics and the protection of technology rights. The current metric stands at 0.28, while the scaling of COPD inhaler sales supports the return on investment in R&D. The share price history is presented below.

Book value represents the aggregate of a company's net assets minus all debt obligations. This metric demonstrates the real value of the business, stripped of market speculation. By analyzing the firm's book capitalization, an investor assesses capital preservation over time. For Verona Pharma plc (VRNA), this basis is critical, as the biotech startup depends on liquidity. Asset stability provides the financial foundation for implementing option programs for key scientists.